828 results about "Pneumonitis" patented technology

The invention provides a metal polyphenol nanoparticle, a preparation method thereof and an application of the metal polyphenol nanoparticle in preparation of a medicine for treating acute lung injury, the metal polyphenol nanoparticle is formed by self-assembly of metal ions and polyphenol, the metal ions are selected from Mg < 2 + >, Zn < 2 + >, Mn < 2 + > or Cu < 2 + >, and the polyphenol is selected from Mg < 2 + >, Zn < 2 + >, Mn < 2 + > or Cu < 2 + >. The polyphenol is selected from epigallocatechin gallate (EGCG), caffeic acid (CA), chlorogenic acid (CGA), gallic acid (GA) and luteolin (LUT). The metal polyphenol nanoparticles are used for preparing a medicine for treating acute lung injury induced by sepsis, pneumonia, serious trauma or inhalation injury, and the medicine further comprises a pharmaceutically acceptable carrier. The metal polyphenol nanoparticles provided by the invention are simple in preparation process and high in biological safety, polyphenol and metal ions synergistically enhance the anti-inflammatory and antioxidant activity, and the metal polyphenol nanoparticles are superior to the single use of polyphenol or metal ions.

The invention provides an atomizing agent containing stem cell exosomes as well as a preparation method and application of the atomizing agent, and belongs to the technical field of exosomes. Ferroferric oxide magnetic particles are prepared, the surfaces of the ferroferric oxide magnetic particles are modified through tannic acid, berberine and adriamycin are loaded, then the ferroferric oxide magnetic particles and the exosome secreted by adipose-derived mesenchymal stem cells are mixed, incubated and centrifuged, the mixture is added into normal saline, uniform ultrasonic dispersion is conducted, and the atomizing agent containing the stem cell exosome is prepared. The prepared atomizing agent containing the stem cell exosome is simple in preparation method and wide in raw material source, the prepared atomizing agent directly enters the lung through spray administration, the unique performance of magnetic targeting drug delivery is achieved, drugs are released in a targeted and fixed-point mode, the drug effect is improved, and the effects of efficiently promoting tumor cell apoptosis and resisting lung cancer and pneumonia are achieved.

The invention relates to the technical field of gene engineering, in particular to a nucleic acid composition, a kit and a detection method for simultaneously and rapidly detecting 16 respiratory tract pathogens. The method specifically comprises the following steps: detecting influenza A virus, influenza B virus, novel coronavirus (ORF1ab gene, N gene), haemophilus influenzae, universal human parainfluenza virus, respiratory syncytial virus, human metapneumovirus, enterovirus, mycoplasma pneumoniae, group A streptococcus, bordetella pertussis, common coronavirus, rhinovirus, bocavirus and adenovirus; a forward primer, a reverse primer and a specific fluorescent probe of streptococcus pneumoniae. Through the PCR reaction, whether respiratory tract pathogens exist or not can be rapidly detected from a specimen at the same time, typing identification of 16 respiratory tract pathogens is carried out at the same time, and compared with a single fluorescent quantitative PCR method, the method is more convenient and rapid, and the cost is lower.

The invention belongs to the field of molecular biological detection, and provides a joint detection composition which mainly utilizes a multiple fluorescent PCR analysis method to detect related pathogens, so as to simultaneously realize detection of coronavirus, bordetella pertussis, group A streptococcus, parainfluenza virus, streptococcus pneumoniae, haemophilus influenzae and group B streptococcus in a single-tube reaction system. Or detecting and distinguishing at least four of chlamydia pneumoniae. Meanwhile, the detection sensitivity of the composition is higher and reaches 500 copies / mL, and the detection is more accurate.

The invention relates to the field of biological medicine, and discloses a method and system for analyzing cough sound by using disease characteristics to diagnose respiratory diseases, and the method comprises the steps: deploying a six-microphone annular array to achieve the precise positioning and triggering of a sound source; self-adaptive spectral subtraction and Wiener filtering cascade are adopted to enhance the audio; segmenting a cough segment based on energy envelope; fusing the Mel-cepstrum, the linear prediction residual error, the harmonic energy ratio and the transient zero-crossing rate to construct a pathological feature matrix; extracting local, medium-range and global time sequence features through a three-branch parallel convolutional network; inputting a disease specific classifier to discriminate asthma, pneumonia and laryngitis respectively, and applying a feature decoupling regular term to improve interpretability. The system correspondingly realizes the modularized processing flow. According to the method, the cough sound collection quality and the disease subtype recognition accuracy in a complex environment are improved, meanwhile, the thermodynamic diagram is output to assist clinical decision making, and the diagnosis credibility and practicability are enhanced.

The invention relates to the technical field of biology, in particular to a multivalent pneumococcal polysaccharide-protein conjugate vaccine for preventing pneumococcal infection and respiratory syncytial virus infection as well as a preparation method and application of the multivalent pneumococcal polysaccharide-protein conjugate vaccine. According to the multivalent pneumococcal polysaccharide-protein conjugate vaccine disclosed by the invention, carrier protein is RSV recombinant protein with immunogenicity; the pneumococcal polysaccharide is connected with the RSV recombinant protein through a covalent bond; the RSV recombinant protein is selected from Pre-F protein, and the amino acid sequence of the RSV recombinant protein is shown as SEQ ID NO: 2 or SEQ ID NO: 3. The conjugate vaccine provided by the invention is an innovative vaccine, two common diseases, namely pneumonia and respiratory syncytial virus infection, can be simultaneously prevented by using one vaccine product, and the number of vaccination times of the vaccine is greatly reduced. According to the invention, the carrier protein in the conjugate vaccine is subjected to mutation modification, so that the carrier protein can maintain structural stability and antigen cluster function in different environments.

The invention provides a composition capable of penetrating an intestinal barrier by oral administration. The composition contains a carrier or an auxiliary material of a targeted Microflod cell Dectin-1 receptor, and one or / and a plurality of medicinal components / components, wherein the carrier or the auxiliary material of the target Microflood cell Dectin-1 receptor is beta-glucan, and the carrier or the auxiliary material of the target Microflood cell Dectin-1 receptor is beta-glucan. The effective components / components are traditional Chinese medicine effective components / components, or / and probiotics, or / and chemical medicine components, or / and biological medicines. The invention relates to a composition capable of realizing oral administration and penetrating through an intestinal barrier, which is based on the discovery of the inventor that the composition reaches colon through gastrointestinal tracts, targets colon Microflood cells, is taken by the Microflood cells, penetrates through the intestinal barrier and enters immune tissue Colonic Patches of a colon submucosa. Based on the research, the composition disclosed by the invention can be used for treating various diseases, such as ulcerative colitis, Crohn's disease, colon cancer, rheumatoid arthritis or bacterial pneumonia after being orally taken and absorbed by rectum.

The present application discloses a detection kit of KL-6 protein on exosomes for auxiliary diagnosis of interstitial lung diseases. A detection method includes: after pretreating the exosome sample with a sample treatment solution, exosomes containing KL-6 protein in the sample react with a coated magnetic bead working solution and a luminescent marker-labeled antibody working solution to form an immunocomplex, and a luminous intensity is detected by using a chemiluminescence method and a concentration value is calculated. The application provides, for the first time, a method for diagnosing interstitial pneumonia using a combination of KL-6 and CA125 proteins on exosomes extracted from blood, or using KL-6 alone.

The invention discloses a pneumovirus gene data multi-view clustering integration method and device and electronic equipment. The method comprises the following steps: constructing a width self-encoder with a width learning network and a global subspace structure; training a width auto-encoder, determining model parameters of the width auto-encoder, inputting multi-view pneumonia gene data into the trained width auto-encoder, and outputting a compressed feature subspace; clustering the compressed feature subspaces to obtain a plurality of basic partitions as integration members of an integration pool; the basic partition is converted into a fuzzy partition matrix, an undirected bipartite graph is constructed based on the integration pool, and connection weights between nodes of the undirected bipartite graph correspond to values in the fuzzy partition matrix; and cutting the undirected bipartite graph into several disjoint sub-graphs, and obtaining a clustering integration result of multi-view pneumonia gene data according to the sample nodes of each sub-graph. According to the method, parameter quantity and computing resources are remarkably reduced, and multi-view clustering analysis of pneumonia gene data is efficiently completed.

The invention discloses a biologically safe and degradable cerium-based tannic acid nano-enzyme as well as a preparation method and application thereof. The nano-enzyme can be administrated through a non-invasive nasal cavity. In an area with excessive ROS, thioketone on CeTA-k1tkP is destroyed, PEG is removed, hydrogen bonds of an amino acid sequence are allowed to form beta-sheet, the beta-sheet is accumulated at an inflammation part, and a fiber or network structure is formed. Meanwhile, CeTA-k1tkP shows enzyme-like capacity, ROS is effectively eliminated, inflammation is effectively relieved, and systemic immunosuppression is avoided at the same time. In an influenza A (Flu A) virus or Sendai virus (SeV) mediated viral pneumonia model, CeTA-k1tkP can generate responsive deformation in inflammatory lung tissues, so that the nano-enzyme effectively decomposes ROS (reactive oxygen species). In addition, the CeTA-k1tkP can relieve bacterial inflammation and reduce tissue damage in a mouse viral pneumonia model with secondary bacterial infection.

The invention provides oral streptococcus ZRSOR-5 as well as a related product, a method and application thereof. The preservation number of the streptococcus oral cavity ZRSOR-5 provided by the invention in the Guangdong Microbial Culture Collection Center is GDMCC No: 65352, and the preservation number of the streptococcus oral cavity ZRSOR-5 provided by the invention is CGMCC No: 65352. Experiments prove that the SOR preparation is prepared by diluting the SOR preparation with normal saline and inhaling the SOR preparation into mice in advance, so that the survival rate of influenza virus infected mice can be remarkably increased, and lung inflammation and virus load can be reduced. When the ZRSOR-5 preparation provided by the invention is used in advance, pneumonia caused by influenza viruses can be resisted.

The present invention relates to an inhibitor of C5a activity and an inhibitor of IL-6 activity for use in the treatment of infectious pneumonia and infectious acute respiratory distress syndrome (ARDS). In further aspects administration regimes and kit of parts are referred to.

The invention belongs to the technical field of biotechnology and genetic engineering, and particularly relates to application of recombinant RASA3 in preparation of a medicine for preventing and treating viral pneumonia. The recombinant RASA3 is used for promoting autophagy degradation of a transcription factor CEBP / beta protein and reducing the expression level of the transcription factor CEBP / beta protein, so that generation of inflammatory factors such as IL-6 is reduced, and inflammatory damage caused by excessive antiviral innate immune response in the virus infection process is improved. The invention provides a novel treatment strategy for inflammatory diseases caused by RNA viruses such as influenza and respiratory syncytial virus infection.

The invention discloses a ferroptosis inhibitor and application of the ferroptosis inhibitor in radiation pneumonitis drugs, and relates to the technical field of biological medicines. The specific preparation method comprises the following steps: adding the ferroptosis inhibitor and the auxiliary agent into the solvent, and dissolving to obtain the ferroptosis inhibitor composition; wherein the ferroptosis inhibitor is isoorientin; the auxiliary agent is a glucosamine derivative; the solvent is a serum-free DMEM culture medium. The ferroptosis inhibitor composition prepared by the method provided by the invention can effectively reduce the rise of active oxygen, ferrous ions and malondialdehyde levels of human pulmonary epithelial cells BEAS-2b and mouse pulmonary epithelial cells MLE-12 caused by irradiation, restore cell mitochondrial membrane potential enrichment and inhibit the expression of various inflammatory factors in irradiated cells; therefore, the process of radiation pneumonitis is remarkably improved, and a new medication strategy is provided for research on radiation pneumonitis drugs.

The invention discloses an alveolar macrophage glycyrrhetinic acid liposome and a preparation method thereof, and belongs to the field of biological medicines. The surface of glycyrrhetinic acid lipidosome is modified with alveolar macrophage targeting molecules, so that the lipidosome can specifically target M1 alveolar macrophages induced by lipopolysaccharide serving as a main component of the outer wall of gram-negative bacteria, entrapped glycyrrhetinic acid is ingested by the alveolar macrophages, M2 polarization is specifically induced, and the specific targeting effect is achieved. Lung inflammatory injury caused by gram-negative bacteria is reduced, lung tissue injury and fibrosis caused by excessive inflammation are prevented, and great significance is achieved for pneumonia caused by gram-negative bacteria.

The invention belongs to the technical field of microorganisms, and particularly relates to application of bifidobacterium longum in preparation of products for prevention, treatment and / or adjuvant treatment of pneumonia. The preservation number of the bifidobacterium longum is GDMCC No: 65969, and the bifidobacterium longum can improve the body weight decrease trend of a pneumonia mouse and reduce the lung visceral organ index of LPS increase; the content of pro-inflammatory factors such as IL-1beta, TNF-alpha and IL-6 in serum is remarkably reduced, mRNA expression of inflammation-related genes such as COX-2, IFN-gamma and TNF-alpha in lung tissue is reduced, and dose dependence is achieved; meanwhile, alveolar structure damage and inflammatory cell infiltration of mouse lung tissue are relieved, and lung tissue pathological damage is repaired. The strain can be used as a core component for developing pneumonia prevention or adjuvant therapy related products, provides a novel microbial intervention means for pneumonia prevention and treatment, and has important application value.

The invention discloses an application of osmundone in preparation of a medicine for treating methicillin-resistant staphylococcus aureus infectious pneumonia. Experimental results of an MRSA mouse pneumonia infection model show that osmundone can significantly reduce the bacterial load in lung tissues, alleviate excessive inflammatory response caused by infection and effectively improve the survival rate of mice. In addition, the invention discloses that osmundone reduces the adhesion and invasion ability of bacteria, reduces the toxicity of the bacteria and plays an antibacterial role by inhibiting the protein activity of staphylococcus aureus Sortase A (SrtA). Different from traditional antibiotics, osmundone does not apply survival pressure to bacteria, so that generation of drug resistance is not easily induced. On the basis, osmundone shows a good application prospect in the aspect of research and development of safe and effective MRSA infectious pneumonia treatment drugs.

The invention relates to the field of preparation of animal husbandry vaccines, in particular to a porcine circovirus, mycoplasma hyopneumoniae and haemophilus parasuis triple vaccine which comprises 30-50 parts of first bacterial liquid containing inactivated haemophilus parasuis; an adjuvant; 40 to 60 parts of a culture solution of a mycoplasma hyopneumoniae culture; 30-40 parts of a second bacterial liquid containing inactivated porcine circovirus; 1 to 10 parts of tween-80; 2-6 parts of aluminum stearate; 1 to 3 parts of interleukin; and 2-4 parts of squalane. The vaccine is mainly applied to prevention of porcine circovirus, mycoplasma hyopneumoniae and haemophilus parasuis for boars and piglets in a pig farm, reduces the multi-system failure syndrome, mycoplasma hyopneumoniae, polyserositis, arthritis and meningitis of weaned piglets in the pig farm and the morbidity of multi-infection-source successive infection, and improves the survival efficiency of the piglets.

The invention provides application of a probiotic composition in preparation of a medicine for preventing and / or treating pneumonia, and belongs to the technical field of biological medicine. The probiotic composition comprises sophora flower bud powder, a broccoli seed aqueous extract, lactobacillus rhamnosus and bifidobacterium animalis subsp. Lactis. Research finds that the probiotic composition can significantly relieve pulmonary edema caused by pneumonia and also can significantly reduce the level of inflammatory factors in pneumonia, so that the probiotic composition has the effect of preventing and / or treating pneumonia, and more choices are provided for clinical drugs for preventing and / or treating pneumonia.

An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 18, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.

The invention relates to dosage forms for daily administration of compounds of formula (A) and formula (I):or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are αvβ6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

The invention discloses an application of a THBS1 inhibitor in preparation of a medicine for preventing or treating lung tissue inflammation induced by novel coronavirus, and provides a related medicine, application and a method, the THBS1 gene inhibitor or a TSP-1 protein inhibitor is used for treating the lung tissue inflammation infected by SARS-CoV-2, the effect is remarkable, and the medicine can be used for preparing medicines for preventing or treating the lung tissue inflammation induced by the novel coronavirus. The SARS-CoV-2 gene is a novel target for treating severe pneumonia caused by SARS-CoV-2 infection.

The embodiment of the invention provides a traditional Chinese medicine preparation for improving lung qi and yin deficiency constitution and a preparation method thereof. The traditional Chinese medicine preparation is prepared from the following raw materials: 1-3 parts of American ginseng, 2-15 parts of Chinese yam, 1.5-9 parts of codonopsis pilosula, 1-6 parts of dendrobium officinale, 1.5-9 parts of rhizoma polygonati, 0.5-2 parts of schisandra chinensis, 2-6 parts of lily, 1-3 parts of pericarpium citri reticulatae, 1-2 parts of liquorice, 1-5 parts of folium mori, 1-3 parts of donkey-hide gelatin, 1-3 parts of mint, 1-6 parts of angelica sinensis and 2-9 parts of coix seeds. Therefore, the traditional Chinese medicine composition has the functions of tonifying qi and yin, clearing heat and moistening lung, replenishing blood and promoting salivation, and relieving cough and reducing sputum, and can be widely applied to chronic cough, various pneumonia, pulmonary tuberculosis, chronic obstructive pulmonary disease, lung malignant tumor, asthma remission period of asthma, respiratory failure and other syndrome-differentiated lung qi and yin deficiency patients.

The invention belongs to the technical field of radiooncology, artificial intelligence and medical image fusion, and particularly relates to a model construction method and system for predicting the radiation pneumonitis risk of a patient receiving immune combined radiotherapy. According to the method, for a non-small cell lung cancer patient receiving immune checkpoint inhibitor (ICIs) combined radiotherapy, clinical information and radiotherapy dose parameters of the patient are collected, a positioning CT image and dynamic immune factor data are simulated, multi-source features including radiomics features, an immune change curve and dose volume indexes are extracted, and a multi-modal fusion prediction model is constructed. The system integrates automatic data input, feature extraction, model training and risk output modules, can output individual radiation pneumonitis risk scores, provides risk grading and dose intervention suggestions, and has high prediction accuracy and clinical interpretability. The method can be widely applied to individualized risk management and precise treatment of non-small cell lung cancer immune combined radiotherapy patients.

The invention discloses lactobacillus paracasei for improving urticaria and Alzheimer's disease and a product, and relates to the technical field of microorganisms. The lactobacillus paracasei NHNK-1701 disclosed by the invention is preserved in the China Center for Type Culture Collection on April 14, 2025, and the preservation number of the lactobacillus paracasei NHNK-1701 is CCTCC (China Center for Type Culture Collection) NO: M 2025765. The NHNK-1701 has the effects of inhibiting the growth of the klebsiella pneumoniae and / or generating alcohol, agglutinating the klebsiella pneumoniae, tolerating 10% of alcohol, reducing alcohol-induced injury of skin cutin barrier and inflammation, reducing alcohol-induced injury of brain microvascular barrier and inflammation, improving the klebsiella pneumoniae-induced injury survival rate of brain microvascular endothelial cells and improving the activity of the brain microvascular endothelial cells. Klebsiella pneumonia induced damage to brain microvascular barriers and inflammation is reduced, and Klebsiella pneumonia induced damage to intestinal barriers and inflammation is reduced.

The invention relates to the technical field of electronic medical record management, in particular to a grading and classifying auxiliary management system for critical case specialized electronic medical record information. Firstly, an electronic medical record of a severe pneumonia patient is acquired through a data acquisition module; further acquiring a vertebra region and a corrected rib region in the target image through a vertebra and rib positioning module; further obtaining a pneumonia lesion index of the target image through a lesion analysis module; finally, in a medical record classification module, the electronic medical records are preliminarily divided into a serious class or a gentle class according to the character information; and classifying the electronic medical records according to the time sequence change characteristics of the pneumonia lesion index of the chest X-ray film of the patient in combination with the distribution characteristics of the sheet density increasing shadow area.

The present invention discloses an application of a traditional Chinese medicine composition in the preparation of a drug for preventing and treating pneumonia caused by the novel coronavirus infection. The traditional Chinese medicine composition of the present invention is mainly composed of forsythia, honeysuckle, isatis root, rhubarb, patchouli, cyperus rotundus, rhodiola rosea and the like, and exerts the overall regulatory advantages of the compound traditional Chinese medicine, organically combines the elimination of pathogenic factors, relief of symptoms and immune regulation to achieve multi-target treatment. Clinical experiments have confirmed that the traditional Chinese medicine composition has a significant inhibitory effect on the prevention and treatment of wild-type and S protein D614G mutant novel coronaviruses, and has a protective effect on the heart and lungs.

The invention relates to application of hydroxynidone to preparation of a medicine for preventing and / or treating radiation-induced pulmonary fibrosis. Pharmacological experiments prove that the hydroxynidone has a definite resisting effect on radioactive rat lung injury including early inflammatory exudation and pulmonary interstitial fibroblast hyperplasia, and can obviously reduce pulmonary alveolar inflammatory cell exudation and reduce the content of TGF beta 1 in inflammatory exudate; the medium and large doses have the effect of delaying the development of interstitial pneumonia towards pulmonary fibrosis; the lesion degrees of the small, medium and large dosage groups are obviously reduced and are in a dose-effect relationship.

The invention discloses application of swertiflavin in preparation of a medicine for treating infectious pneumonia caused by methicillin-resistant staphylococcus aureus, and relates to the technical field of medicine. It is found for the first time that swertiflavin can significantly reduce the toxicity of staphylococcus aureus by inhibiting the activity of ClpP protein in MRSA. In addition, the swertiflavin shows a remarkable protection effect in the treatment of the MRSA infectious pneumonia. Specifically, the swertiflavin not only can relieve the injury degree of lung tissues, but also can reduce infiltration and aggregation of inflammatory cells in the lung. The discovery shows that the swertiflavin has potential application value in the field of anti-infection treatment. The invention provides a novel treatment strategy, namely, swertiflavin is used as an active ingredient for preparing the medicine for treating the staphylococcus aureus infectious pneumonia.

The present invention relates to a composition for treatment of coronavirus disease 2019 (COVID-19) containing taurodeoxycholic acid (TDCA) or a pharmaceutically acceptable salt thereof as an active ingredient. Specifically, an early full recovery effect has been confirmed through the efficacy of treating clinical symptoms caused by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, alleviating inflammation, and inhibiting inflammatory cytokines using a pharmaceutically acceptable salt of taurodeoxycholic acid, and thus the taurodeoxycholic acid or a pharmaceutically acceptable salt thereof can be used as an active ingredient in a composition for prevention or treatment of lower respiratory tract infectious diseases, including coronavirus disease 2019.